APIs

Product Description

Recipharm operate facilities which can manufacture several products at a time, handling high pressure, high temperature (up to 150 degrees Celsius) and low temperature (down to –80 degrees Celsius) reactions. Different batch sizes are available ranging from 20L to 6000L, supporting early development and commercial needs. 
Recipharm also offer:

  • Manufacturing of general APIs and some hormones
  • API development with exploratory work, optimisation and up-scaling of early syntheses
  • A dedicated beta lactam plant for the lyophilisation of bulk API

Recipharm AB

  • SE
  • 2015
    On CPhI since
  • 5000+
    Employees

Recipharm AB

  • SE
  • 2015
    On CPhI since
  • 5000+
    Employees

More Products from Recipharm AB

  • Solids

    Product Solids

    Recipharm offers pharmaceutical contract development and manufacturing of large commercial batch sizes of tablets, capsules or powders. 

    Recipharm work with:
    • General APIs as well as some special substances
    • Conventional technologies, including fluid bed granulation and water/organic solvents based coating
    • State of the art facilities for manufacturing pellets with layering technology
    • High performance, fully automated equipment for sachets allowing for our expertise in large volume powder products
  • Ophthalmics

    Product Ophthalmics

    Recipharm offers pharmaceutical contract development and manufacturing in ophthalmics including, sterile manufacturing of eye and ear drops in plastic multi-dose containers and  blow-fill-seal technology for single and as multi-dose use.
  • Semi-solids

    Product Semi-solids

    Recipharm offers pharmaceutical contract development and manufacturing of semi-solids including, APIs, creams, emulsions, gels, ointments, aerosols and suppositories. We have the capability to fill products in aluminum tubes, plastic tubes, syringes, aluminum cans, PVC or aluminum blisters packaging, and also offer a unique topical patch manufacturing system for sustained drug release.
  • Injectables

    Product Injectables

    Recipharm has extensive experience in the injectables area and supplies small volume parenterals in ampoules and vials, as well as in cartridges. State of the art leak detection and automatic inspection equipment is used and Recipharm’s full service offering is complete with secondary packaging and temperature controlled storage.
    • Lyophilisation - Recipharm offers state-of-the-art freeze drying processing
    • Aseptic fill of sterile powder - Dry powder filling is performed in state of the art equipment. Dedicated facilities are available for penicillins and cephalosporins for worldwide supply. General APIs are filled in Recipharm’s WHO-certified facility in Paonta Sahib
    • Focus on drug delivery - from a specialised facility, development of pyrogen free drug carrying polymers for controlled release of injectable products is offered

  • Liquids

    Product Liquids

    Recipharm offers pharmaceutical contract development and manufacturing of liquids, sprays and aerosols, with a broad range of equipment and compounding vessels from 100L to 5000L.
  • Serialisation

    Product Serialisation

    Recipharm  have committed to invest in and fully implement the technical solutions needed to comply with global requirements for pharmaceutical serialisation and track and trace. Our serialisation offering includes:
    • Experience in already providing serialised products to Turkey, Korea and China
    • Serialisation capabilities in 15 European locations and over 70 production lines
    • A standard solution to meet all requirements which can be adapted to specific needs
    • A novel pricing model with no major upfront investments
    • Expertise in understanding market requirements
    To learn more about our full serialisation offering, visit our website.

  • Synthetic chemistry

    Product Synthetic chemistry

    Recipharm offer a range of synthetic chemistry services through our global development facilities including advanced lead optimisation medicinal chemistry, process development and tech transfer to large scale GMP-manufacturing and other specialties.
  • Analytical development

    Product Analytical development

    Recipharm offer analytical support for drug discovery, pharmaceutical development and manufacturing through our global development facilities.
  • Formulation Development

    Product Formulation Development

    Recipharm offer formulation development services for all dosage forms. We develop everything from simple formulations for early studies to more complex formulations suited for commercialisation.
  • Clinical Supply

    Product Clinical Supply

    Recipharm have more than 20 years experience supplying clinical trial material to our clients. Our development facilities cater for a range of clinical trials from preclincal to smaller Phase III trials. We also offer commercial manufacturing for very large clinical batches.
  • Recipharm Inhalation Solutions™

    Product Recipharm Inhalation Solutions™

    Recipharm Inhalation Solutions™ offers an end-to-end service for inhalation drug products and devices spanning early stage development to commercial manufacture.Our dedicated team offers pharmaceutical companies a seamless outsourcing service from early stage development through to commercial manufacturing for inhalation products.Our depth of knowledge means we can overcome the challenges associated with inhalation drug products and devices. By developing inhalation products with the device and commercial manufacture in mind we eliminate hurdles and reduce time to market.
    In 2020, Recipharm acquired Consort Medical adding additional CDMO services and medical device expertise to the Group. Through Bespak by Recipharm, we deliver market leading design, development and manufacture of drug delivery devices to the global pharmaceutical market. This includes inhaler and nasal technologies via Recipharm Inhalation Solutions™.

  • Recipharm Analytical Solutions™

    Product Recipharm Analytical Solutions™

    Through Recipharm Analytical Solutions™, we support customers with stand-alone analytical requirements. Our analytical development team has experience from developing hundreds of analytical methods every year, supporting development of formulations ranging from powder in capsules and IV solutions to ER tablets and dry powder inhalers. This means our 160-strong team of chemists are prepared for any challenge. The size and flexibility of our labs enable rapid project initiation and parallel activities to be performed. Combined with our track record and expertise, our offering can help decrease time-to-market. At Recipharm, we have several state-of-the-art laboratories and stability chambers enabling more than 250 concurrent ongoing stability studies. By utilising our expertise, we help clients to combat resource challenges while reducing timelines and costs.

Recipharm AB resources

  • Sponsored Content Key considerations to develop effective analytical methods for your drug project

    A summary exploring Recipharm’s key considerations when it comes to developing effective analytical methods for drug projects.
  • Brochure Recipharm Analytical Solutions™

    Through Recipharm Analytical Solutions™, we support customers with stand-alone analytical requirements.Our analytical development team has experience from developing hundreds of analytical methods every year,supporting development of formulations ranging from powder in capsules and IV solutions to ER tablets and drypowder inhalers. This means our 160-strong team of chemists are prepared for any challenge.
  • News CPhI Monthly Podcast: Selecting the Right CDMO Outsourcing Partner

    With so many outsourcing options available, selecting the CDMO that is the right fit for any particular sponsor company can be a challenging task.
  • Brochure Recipharm's full service offering

    Your innovative drug. Our world-class production facilities. Discover the genius of working together.
  • News Sterile manufacturing Annex 1 amendments: what, why and how explained

    In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update.
  • Brochure Successful drug development in the early clinical phase

    Moving from drug discovery into the early clinical development can be both challenging and time consuming without access to the necessary expertise. To perform a phase 1 study successfully, having drug substances and drug products (of the right quality is crucial. In addition, the right knowledge and resources must also be in place, to ensure the fastest route to clinic.
  • Sponsored Content CPhI Monthly Podcast: Selecting the Right CDMO Outsourcing Partner

    Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and scaling up to the commercial level are just three examples.
  • Brochure Exploring new propellants

    Over the years, the prominence placed on creating a ‘greener’ future has increased dramatically. As a result, companies globally are facing growing pressure to adopt sustainable processes and reduce their carbon footprint. At Recipharm, we are taking a proactive approach to the situation and will be ready to adapt to any future changes of legislations, as well as supply challenges. 
  • Sponsored Content Sterile manufacturing Annex 1 amendments: what, why and how explained

    In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update. 
  • Brochure Development of cannabinoids

    At Recipharm, we have the experience and appropriate licencing to support both development and commercial supply of cannabinoids. And, to further assist researchers and pharma companies working in this field, we have also developed new, synthetic routes to five different cannabinoids, including CBDA, CBGA, and three metabolites. In addition, we have identified a novel, scalable, synthetic route to CBD.
  • News Recipharm expands its analytical services offering in India

    The CDMO inaugurates its new analytical laboratory under Recipharm Analytical Solutions
  • Brochure Controlled substances

    At Recipharm we have been supporting customers with their controlled substance projects for more  than 25 years. Our state-of-the-art manufacturing facilities have the infrastructure to safely and securely handle potent materials and we are approved to import, store, manufacture and export Class 1–5 controlled substances.
  • News Second Curaleaf GMP cannabis facility gains Spanish approval

    Medalchemy facility now fully licensed to import, cultivate, extract, manufacture and export medical cannabis flower and extracts
  • Brochure Clinical trial material

    We understand the need for high quality and timely delivery and work with our customers throughout their development projects to ensure success. Our dedicated development facilities, cleanrooms for cGMP production of solid, liquid, and semi-solid formulations and sterile suites to produce sterile vials, allow us to cater for a range of clinical trials from Phase I to smaller Phase III trials. Large trials will be supplied from our commercial manufacturing sites.
  • News Recipharm selected to operate new fill/finish facility in Morocco

    Move is part of US$500 million five-year investment programme by Moroccan government and consortium to establish vaccine and biotherapeutic manufacturing capacity in the country
  • Brochure Inhalation device design, development and manufacture

    Bespak by Recipharm delivers market leading design, development, and manufacturing services for inhalation drug delivery devices to the global pharmaceutical market, at low, medium and high volume manufacturing scales.
  • News Resyca joint venture ready to push the boundaries of softmist technology

    Joint venture between Recipharm and Medspray could provide significant advantages for patients and the environment, companies say
  • Brochure How to speed up vaccine development and production with genetic vaccine technology

    We explore the challenges and pitfalls in developing new genetic vaccines, and in manufacturing them following approval. In addition, we discuss how strategic partnerships with expert contract development and manufacturing organisations (CDMOs) can support vaccine developers to bring their innovations to market.
  • News Top 5 Industry Content Reads on CPhI Online This Month

    If you’re looking for news, product information and market trends from leading pharma companies, the CPhI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

  • Brochure Self-administered injectable drugs: choosing the right delivery device for your product

    In this eBook, we will explore how drug developers can best identify and develop the right drug delivery device for their self-administered injectable products. We will also highlight the potential disadvantages of poorly designed devices. We will provide practical, straightforward advice around choosing the right device for the needs of self-injected products, and the considerations that need to be made to ensure optimum performance and long-term patient acceptance as well as highlight the added value of engaging device experts early in the design and development process.
  • News Recipharm signs up for aseptic fill-finish manufacturing of Moderna COVID-19 vaccine

    The CDMO is already making certain investments to enable technology transfer and scale-up to commence imminently.
  • Brochure Drug development for start-ups

    While developing a new pharmaceutical product is one of the most interesting and rewarding activities to partake in, it is also extremely challenging. It is a given that drug development projects will not always succeed and the more innovative they are, the higher the likelihood of failure. There is no way to eliminate the risk of failure. However, there are ways to reduce these risks.
  • News Recipharm and Medspray establish joint venture to exploit novel softmist technology

    Resyca BV will provide a "unique offering" to the market — environmentally friendly, softmist spray nozzle technology for pharmaceutical applications.
  • Brochure Environmentally friendly propellants Open Environmentally friendly propellants configuration options

    In recent years there has been a global focus on adopting sustainable processes, reducing carbon footprint and ultimately creating a ‘greener’ world for the future. The prominence placed on discussion around environmentally friendly operations has prompted widespread reviews of current practices across all industries, including the pharmaceutical industry.
  • News Recipharm invests in its pMDI valves production capacity

    The expansion will bolster the CDMO's offering by ensuring it can fulfil the forecasted increase in demand for respiratory devices.
  • Technical Data Recipharm Inhalation Solutions™

    At Recipharm, we support inhalation product developmentand manufacturing through our end-to-end service offering,Recipharm Inhalation Solutions™.
  • News Recipharm’s proprietary molecule Erdosteine has been positively tested as part of COVID-19 treatment

    Recipharm is pleased to announce that the results of the study with Erdosteine as an add-on treatment for COVID-19 patients are now available.
  • Technical Data Pilot plant

    nhalation development and manufacturing for early and late-stage clinical supply.

    Recipharm Inhalation Solutions™ offers comprehensive contract development and manufacturing solutions for early and late-phase clinical supply from our stand-alone pilot plant as part of our integrated inhalation offering.

  • News Recipharm to boost sterile liquids manufacturing capacity

    The investment will support increased demand and help to secure new business at its Kaysersberg facility.
  • Technical Data Innovation services

    Bespak by Recipharm delivers market leading design, development, and manufacturing services for drug delivery devices to the global pharmaceutical market. Based in Cambridge, UK, our innovation centre is home to a team with diverse skills and expertise. Established to create new technologies that form the core around which we build and develop reliable, robust products, capable of meeting and exceeding our customers’ expectations with a focus on parenteral, nasal and ophthalmic routes of administration.
  • News Recipharm invests EUR 2.6 million in Kaysersberg facility

    Global contract development and manufacturing organisation (CDMO), Recipharm, has announced a EUR 2.6 million investment for additional manufacturing capacity to support increased demand into its Kaysersberg facility.
  • Technical Data Inhalation and nasal product manufacturing

    Recipharm offers inhalation and nasal product manufacturing in compliance with FDA and MHRA regulations. We offer contract manufacturing, packaging and supply to the global pharmaceutical market.Our dedicated team has more than 50 years’ experience in manufacturing inhalable products and supports our customers with the development and commercialisation of metered dose inhalers, dry powder inhalers and nasal sprays.
  • News Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR[®]-COV19 (ARCT-021) vaccine candidate

    Recipharm, a leading contract development and manufacturing organisation (CDMO) has entered into an agreement with Arcturus Therapeutics, a leading U.S. based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. 
  • Technical Data Device contract manufacturing

    Bespak by Recipharm delivers market leading design, development, and manufacturing services for drug delivery devices to the global pharmaceutical market, at low, medium and high volume manufacturing scales. We have extensive experience in producing medical devices, including inhalers, nasal technologies, and auto-injectors, for some of the world’s leading pharmaceutical companies.
  • News BIAL and Recipharm expand long-term supply agreement for opicapone API

    Portuguese pharma company, BIAL, and global contract development and manufacturing organisation (CDMO), Recipharm, have expanded a long-term agreement for the global manufacturing and supply of BIAL’s proprietary molecule opicapone.
  • Technical Data Extractables and Leachables testing

    Our E&L testing capabilities include analytical techniques designed to identify and test a wide range of additives and impurities, which could migrate from packaging to the drug product, potentially affecting drug efficacy and patient safety.
  • News Sobrera Pharma and Recipharm in collaboration to advance a new treatment for patients with Alcohol Use Disorder

    Swedish life science company, Sobrera Pharma, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development and manufacturing of SO-001, a new oral treatment for Alcohol Use Disorder (AUD).
  • News Introducing Bespak by Recipharm

    In February 2020, Recipharm acquired Consort Medical plc, which included Bespak. The move was designed to strengthen Recipharm’s position as a leading inhalation company and one of the largest CDMOs in the world.
  • Video Webinar - Tomorrow’s medicines with today’s drug substances

    Developing new pharmaceutical products is difficult in today’s environment. Products based on new chemical entities (NCEs) have the potential to generate huge profits, but the development process is long (often 10 years), costs are high (about $ 1 billion) and the risk of failure is great. In contrast, the development of generics is faster and much less costly. However, profits are generally small with a decreasing trend due to fierce competition. An interesting segment is new products using new dosage forms and existing active pharmaceutical ingredients (APIs) - known as “drug delivery innovation.’ Such products offer an alternative as development timelines are shorter, costs are significantly less, and a certain degree of market exclusivity can be gained. Consequently, these products can be highly profitable.

Recommended products